R&D Portfolio

Arbutus' portfolio of assets includes a pipeline focused on curing HBV. To achieve an HBV cure a combination of products that affect the main drivers of HBV need to be utilized. Specifically, we have products that address HBV persistence in antiviral replication, immune reactivation and the presence of cccDNA.